Publications
“The Mycobacterium abscessus cytochrome bcc:aa3 oxidase structure paves the way for a new agent targeting subunit QcrB.” Mathiyazakan, V., Tan, E.X., Moraski, G., Basak, S., Saw, W.G., Pethe, K., Grüber G. Nature Communications. 2026, https:// doi.org/10.1038/s41467-026-70805-5.
“A bioluminescence-based chemical screen identifies a bactericidal naphthalen-1- ylmethanamine scaffold targeting MmpL3 in Mycobacterium abscessus.” Samsher, S., Sorayah, R., Chen, Y., Mulholland, C. V…Moraski, G., Pethe, K. Cell Reports. 2026, 45(5), https://doi.org/10.1038/s41467-026-70805-5
“Fifteen Years, One Mission: Innovative, Inspirational, and Impactful Discoveries.” Bigi-Botterill, S.V., Borsari, C., Dombrowski, A. W., Estrada, M. A., Farrell, M. P., Riley, A. P., Woodland, J. G. ACS Med. Chem. Lett. 2025, https://doi.org/10.1021/ acsmedchemlett.5c00709. [My research paper was highlighted as most cited/ impactful over 15 years.]
“A bioluminescence-based chemical screen identifies a bactericidal naphthalene scaffold targeting MmpL3 in Mycobacterium abscessus.” Singh, S., Sorayah, R., Yushu Chen, Y., Mulholland, C. V., Daher, W., Pee, C. J. E., Moraski, G.C. et al bioRxiv, 2025, 2025-10.
“Expanding the Landscape of Dual Action Antifolate Antibacterials through 2, 4-Diamino −1, 6-dihydro-1, 3, 5-triazines.” Georgiades, J.D., Moraski, G.C., Wencewicz T.A., et al. ACS Infectious Diseases, 2025, 11(1), 689−702.
“GaMF1. 39’s antibiotic efficacy and its enhanced antitubercular activity in combination with clofazimine, Telacebec, ND-011992, or TBAJ-876.” Ragunathan, Priya, et al. Microbiology Spectrum, 2023, e02282-23.
“On the Hunt for Next-Generation Antimicrobial Agents: An Online Symposium Organized Jointly by the French Society for Medicinal Chemistry (Société de Chimie Thérapeutique) and the French Microbiology Society (Société Française de Microbiologie) on 9–10 December 2021.” Antraygues, Kevin, et al. Pharmaceuticals, 2022, 15(4), 388.
“Syntheses and Studies of Deuterated Imdiazo[1,2-a]pyridine-3-carboxamides with Potent Anti-tuberculosis Activity and Improved Metabolic Properties.” Liu, R., Marshall, K., Ma, R., Pham, K. L. T., Shetye, G., Liu, Z., Cho, S., Jeong, H., Franzblau, S. G., Moraski, G. C., Miller, M.J. Bioorganic Chemistry, 2022, 106074.
“The QcrB Inhibitors TB47 and Telacebec Do Not Potentiate the Activity of Clofazimine in Mycobacterium abscessus.” Sorayah, R., Moraski, G. C., Barkan, D., Pethe, K. Antimicrobial Agents and Chemotherapy, 2021, 65(12), e00964-21.
“SynthesesandStructureActivityRelationshipsofNPhenethylQuinazolin4ylAmines Garrett C. Moraski (CV 2025) 4 Hopfner, S. M., Lee, B. S., Kalia, N. P., Miller, M. J., Pethe, K., Moraski, G. C. Applied Sciences, 2021, 11(19), 9092.
“Hydride-induced Meisenheimer complex formation reflects activity of nitro aromatic anti-tuberculosis compounds.” Liu, R., Markley, L., Miller, P. A., Franzblau, S., Shetye, G., Ma, R., Savková, K., Mikušová, K., Lee, B.S., Pethe, K. Moraski, G.C., Miller, M. J. RSC Medicinal Chemistry, 2021, 12(1), 62-72. Cover article.
“Structure guided generation of thieno[3,2-d]pyrimidin-4-amine Mycobacterium tuberculosis bd oxidase inhibitors.” Hopfner, S. M., Lee, B. S., Kalia, N. P., Miller, M. J., Pethe, K., Moraski, G.C. RSC Medicinal Chemistry, 2021, 12(1), 73-77.
“Dual inhibition of the terminal oxidases eradicates antibiotic‐tolerant Mycobacterium tuberculosis.” Lee, B. S., Hards, K., Engelhart, C. A., Hasenoehrl, E. J., Kalia, N. P., Mackenzie, J. S., Sviriaeva, E., Chong, S. M. S., Manimekalai, M. S. S., Koh, V. H. Chan, J., Moraski, G. C., Pethe, K. EMBO Molecular Medicine, 2021, 13(1), e13207.
“Intracellular and In Vivo Evaluation of Imidazo[2,1-b]thiazole-5-carboxamide Antituberculosis Compounds.” Moraski, G. C., Deboosère, N., Marshall, K. L., Weaver, H. A., Vandeputte, A., Hastings, C., Woolhiser, L., Lenaerts, A. J., Brodin, P. Miller, M. J. PLOS One, 2020, 15(1), e0227224.
“Carbon metabolism modulates the efficacy of drugs targeting the cytochrome bc1: aa3 in Mycobacterium tuberculosis.” Kalia, N. P., Lee, B. S., Ab Rahman, N. B., Moraski, G. C., Miller, M. J., Pethe, K. Scientific reports, 2019, 9(1), 8608.
“PvdF of pyoverdin biosynthesis is a structurally unique N10-formyltetrahydrofolatedependent formyltransferase.” Kenjić, N., Hoag, M.R., Moraski, G.C., Caperelli, C.A., Moran, G.R. and Lamb, A.L. Archives of Biochemistry and Biophysics, 2019, 664, 40-50.
“Targeting the Mycobacterium ulcerans cytochrome bc1:aa3 for the treatment of Buruli ulcer.” Scherr, N., Bieri, R., Thomas, S. S., Chauffour, A., Kalia, N-P., Schneide, P., Ruf, M. T., Lamelas, A., Manimekalai, M. S. S., Grüber, G., Ishii, N., Suzuki, K., Tanner, M., Moraski, G. C., Miller, M. J., Witschel, M., Jarlier, V., Pluschke, G., Pethe, K. Nature Communications, 2018, 9(1), 5370.
“Imidazopyridine compounds inhibit mycobacterial growth by depleting ATP levels.” O’Malley, T., Alling, T., Early, J. V., Wescott, H. A., Kumar, A., Moraski, G. C., Miller, M. J., Masquelin, T., Hipskind, P. A., Parish, T. Antimicrobial Agents and Chemotherapy. 2018, 62(6), e02439-17.
“Decarboxylation involving a ferryl, propionate, and a tyrosyl group in a radical relay yields heme b.” Streit, B. R., Celis, A. I., Moraski, G. C., Shisler, K. A., Shepard, E. M., Rodgers, K. R., Lukat-Rodgers, G. S., DuBois, J. L. Journal of Biological Chemistry, 2018, 293(11), 3989-99.
“Structure-based mechanism for oxidative decarboxylation reactions mediated by amino acids and heme propionates in coproheme decarboxylase (HemQ).” Celis, A. I., Gauss, G. H., Streit, B. R., Shisler, K., Moraski, G. C., Rodgers, K. R., Lukat-Rodgers, G . S., Peters, J. W. and DuBois, J. L. Journal of the American Chemical Society, 2017, 139(5), 1900-1911.
“Preparation and Evaluation of Potent Pentafluorosulfanyl‐Substituted Anti‐Tuberculosis Compounds.” Moraski, G. C., Bristol, R., Seeger, N., Boshoff, H. I., Tsang, P. S. Y., Miller, M. J. ChemMedChem, 2017, 12(14), 1108-1115. Cover article.
“Imidazo[1,2-a]pyridine-3-Carboxamides Are Active Antimicrobial Agents against Mycobacterium avium Infection In Vivo.” Moraski, G. C., Cheng, Y., Cho, S., Cramer, J. W. Godfrey, A., Masquelin, T., Franzblau, S. G., Miller, M. J., Schorey, J. Antimicrobial agents and chemotherapy 2016, 60(8), 5018-5022.
“A Structure-Based Mechanism for Oxidative Decarboxylation Reactions Mediated by Amino Acids and Heme Propionates in Coproheme Decarboxylase (HemQ).” Celis, A. I., Gauss, G. H., Streit, B. R., Shisler, K., Moraski, G. C., Rodgers, K. R., DuBois, J. L. J. Am. Chem. Soc., 2016, 139(5), 1900-11. DOI: 10.1021/jacs.6b11324.
“Arrival of Imidazo[2,1-b]thiazole-3-carboxamides: Potent Anti-tuberculosis Agents that Target QcrB.” Moraski, G. C.; Seeger, N.; Miller, P. A.; Oliver, A.; Boshoff, H. I.; Cho, S.; Mulugeta, S.; Anderson, J. R.; Franzblau, S. G.; Miller, M. J. ACS Inf. Dis. 2016, 2 (6), pp 393–398. Cover article.
“Unusual Peroxide-Dependent, Heme-Transforming Reaction Catalyzed by HemQ,” Celis, A. I., Streit, B. R.; Moraski, G. C; Kant, R.; Lash, T. D.; Lukat-Rodgers, G. S.; Rodgers, K. R.; DuBois, J. L. Biochemistry,2015, DOI: 10.1021/acs.biochem.5b00492.
“Putting TB to Rest: Transformation of the Sleep Aid, Ambien and “Anagrams” Generated Potent Anti-tuberculosis Agents.” Moraski, G. C.; Miller, P. A.; Bailey, M.-A.; Ollinger, J.; Parish, T.; Boshoff, H. I.; Sanghyun, C.; Anderson, J. R.; Mulugeta, S.; Franzblau, S. G.; Miller, M. J. ACS Infectious Diseases, 2015. DOI: 10.1021/id500008t.
“Bactericidal Activity of an Imidazo[1,2-a]pyridine Using a Mouse M. tuberculosis Infection Model.” Cheng, Y., Moraski, G. C., Cramer, J., Miller, M. J., Schorey, J. S. PLoS One, 2014, 9, No. e87483.
“Scaffold-switching: An exploration of 5, 6-fused bicyclic heteroaromatics systems to afford antituberculosis activity akin to the imidazo[1,2-a]pyridine-3-carboxylates.” Moraski, Garrett C., Allen G. Oliver, Lowell D. Markley, Sanghyun Cho, Scott G. Franzblau, and Marvin J. Miller. Bioorganic & Medicinal Chemistry Letters, 2014, 15, 3493-3498.
“Advancement of Imidazo[1,2-a]pyridines with Improved Pharmacokinetics and Nanomolar Activity Against Mycobacterium tuberculosis.” Moraski G. C., Markley L. D., Cramer J., Hipskind P. A., Boshoff H., Bailey M., Alling T., Ollinger J., Parish T., Miller M. J. ACS Med Chem Lett., 2013, 4, 675-679. PMID: 23930153.
“A dual read-out assay to evaluate the potency of compounds active against Mycobacterium tuberculosis.” Ollinger J., Bailey M. A., Moraski G. C., Casey A., Florio S., Alling T., Miller M. J., Parish T. PLoS One, 2013, 8, e60531. doi: 10.1371/journal.pone.0060531. PMID: 23593234.
“Thiolates Chemically Induce Redox Activation of BTZ043 and Related Potent Nitro Aromatic Anti-Tuberculosis Agents.” Tiwari, R.; Moraski, G. C.; Krchnak, V.; Miller, P.; Möllmann, U.; Colon-Martinez, M.; Herrero, E.; Oliver, A.; Miller, M. J. J. Am. Chem. Soc., 2013, 135, 3539 – 3549. PMID: 23402278.
“Allylic thiocyanates as a new class of antitubercular agents.” Silveira, G. P.; Ferreira, M.; Fernandes, L.; Moraski, G. C.; Cho S.; Hwang, C.; Franzblau, S. G.; Så, M. M. Bioorg. Med. Chem. Lett. 2012, 20, 6486 – 6489. PMID: 22967767.
“Syntheses and biological studies of novel spiropiperazinyl oxazolidinone antibacterial
agents using a spirocyclic diene derived acylnitroso Diels-Alder reaction.” Ji, C.; Lin, W.;
Moraski, G. C.; Thanassi, J. A.; Pucci, M. J.; Franzblau, S. G.; Möllman, U.; Miller, M. J.
Bioorg. Med. Chem., 2012, 20, 3422-8. doi: 10.1016/j.bmc.2012.04.026.
“Generation and exploration of new classes of antitubercular agents: The optimization of oxazolines, oxazoles, thiazolines, thiazoles to imidazo[1,2-a]pyridines and isomeric 5,6-fused scaffolds.” Garrett C. Moraski, Lowell D. Markley, Mayland Chang, Sanghyun Cho, Scott G. Franzblau, Chang Hwa Hwang, Helena Boshoff, and Marvin J. Miller, Bioorgan. Med. Chem., 2012, 7, 2214- 2220.
“One Step Syntheses of Nitrofuranyl Benzimidazoles that are Active Against Multi-Drug Resistant Bacteria.” Garrett C. Moraski, Jane A. Thanassi, Steven D. Podos, Michael J. Pucci and Marvin J. Miller, J. Antibiotics, 2011, 1- 5. doi: 10.1038/ja.2011.67.
“Advent of Imidazo[1,2-a]pyridine-3-carboxamides with Potent Multi- and Extended Drug Resistant Antituberculosis Activity.” Garrett C. Moraski, Lowell D. Markley, Philip A. Hipskind, Helena Boshoff, Sanghyun Cho, Scott G. Franzblau and Marvin J. Miller, ACS Med. Chem. Lett., 2011, 6,466-470.
“Design, Synthesis, and Study of a Mycobactin-Artemisinin Conjugate That Has Selective and Potent Activity against Tuberculosis and Malaria.” Marvin J Miller, Andrew J Walz, Helen Zhu, Chunrui Wu, Garrett Moraski, Ute Möllmann, Esther M Tristani, Alvin L Crumbliss, Michael T Ferdig, Lisa Checkley, Rachel L Edwards and Helena I Boshoff, J. Am. Chem. Soc., 2011, 33, 2076-9
“N-((1-Benzyl-1H-1,2,3-triazol-4-yl)methyl)arylamide as a New Scaffold that Provides Rapid Access to Antimicrotubule Agents: Synthesis and Evaluation of Antiproliferative Activity Against Select Cancer Cell Lines.” Jonathan A Stefely, Rahul Palchaudhuri, Patricia A Miller, Rebecca J Peterson, Garrett C Moraski, Paul J Hergenrother and Marvin J Miller, J. Med. Chem, 2010, 53, 3389-95.
“Syntheses and Biological Evaluation of Novel Heterocyclic Antituberculosis Agents Derived from Oxazoline and Oxazole Benzyl Esters,” Garrett C. Moraski, Mayland Chang, Adriel Villegas-Estrada, Scott G. Franzblau, Ute Möllmann and Marvin J. Miller, Euro. J. Med. Chem. 2010, 45, 1703-16.
“Utilization of the Suzuki Coupling to Enhance the Antituberculosis Activity of Aryl Oxazoles,” Garrett C. Moraski, Scott G. Franzblau and Marvin J. Miller, Heterocycles, 2009, 80, 977-88.
“Syntheses of dideoxymycobactin antigens presented by CD1a reveals T cell fine specificity for natural lipopeptide structures,” David C. Young, Anne Kasmar, Garrett Moraski, Tan-Yun Cheng, Andrew J. Walz, Jingdan Hu, Yanping Xu, Gregory W. Enders, Adam Uzielbo, Dirk Zajonc, Catherine E. Costello, Marvin J. Miller, Branch Moody, J. Biol. Chem. 2009, 284, 25087-96.
“Utilization of microbial iron assimilation processes for the development of new antibiotics and inspiration for the design of new anticancer agents,” Miller M, Zhu H, Xu Y, Wu C, Walz A, Vergne A, Roosenberg J, Moraski G, Minnick A, McKee-Dolence J, Hu J, Fennell K, Kurt Dolence E, Dong L, Franzblau S, Malouin F, Mollmann U. Biometals. 2009, 22, 61-75.
“Noclinical pharmacology of a selective PDGFR tyrosine kinase inhibitor, CP-868,596,” Whalen, P. M.; Soderstrom, E. A.; Lin, J.; Moraski, G.; Kath, J. C.; Boyden, T. L.; Desrosiers, E. S. et al. Clinical Cancer Research, 2005, 11(24), 9035S-0935S Part 2 Suppl.
“Antiangiogenic and Antitumor Activity of a Selective PDGFR Tyrosine Kinase Inhibitor, CP-673,451,” Roberts, W. G.; Whalen, P. M.; Soderstrom, E.; Moraski, G.; Lyssikatos, J. P.; Wang, H.-F.; Cooper, B. Baker, D. A.; Savage, D.; Dalvie, D.; Atherton, J. A.; Ralston, S.; Szewc, R.; Kath, J. C.; Lin, J. Soderstrom, C.; Tkalcevic, G.; Cohen, B. D.; Pollack, V.; Barth, W.; Hungerford, W.; Ung, E. Cancer Research, 2005, 65(3), 957-966.
“Streamlined Processes for the Synthesis of a Farnesyl Transferase Inhibitor Drug Candidate,” Andresen, B. M.; Couturier, M.; Cronin, B.; D’Occhio, M. Ewing, M. D.; Guinn, M.; Hawkins, J. M., Jasys, V. J.; LaGreca, S. D.; Lyssikatos, J. P.; Moraski, G.; Ng, K.; Raggon, J. W.; Stewart, A. M.; Tickner, D. L.; Tucker, J. L.; Urban, F. J.; Vazquez, E.; Wei, L. Organic Process Research & Development, 2004, 8(4), 643-650.